Trial results show leishmaniasis vaccine is safe and induces immune responses in patients

Leishmaniasis

The results of the first clinical trial of a new vaccine for a neglected tropical disease have demonstrated that it is safe and induces immune responses in patients with the infection.

There are currently no vaccines to prevent leishmaniasis which is spread by the bite of sand flies and existing drugs have many side effects and are difficult to administer.

The potential new vaccine was developed by researchers at the Hull York Medical School, which is the joint medical school of the Universities of Hull and York.

Professor Paul Kaye from the Hull York Medical School was the principal investigator on the Wellcome Trust Translation Award that funded the development of the vaccine.